[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-32364":3,"doc-seo-32364":27},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"file_id":15,"file_url":16,"file_type":17,"file_size":18,"view_count":4,"is_deleted":4,"is_public":19,"is_downloadable":19,"audit_status":19,"page_count":20,"language":21,"language_code":22,"table_of_contents":23,"faqs":24,"seo_title":13,"seo_description":14,"update_tm":25,"read_time":26},32364,1099514067438,"River Wang","https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542",7,"Healthcare","Decongestion in Heart Failure: Medical and Device Therapies","Heart failure is a leading cause of hospitalization worldwide, and congestion is the dominant driver of symptoms and admissions. Loop diuretics remain the core treatment, yet many patients are discharged with residual congestion, which sustains symptoms and increases adverse outcomes and readmissions. Multiple medical and device approaches are under study to improve decongestion and subsequent heart failure outcomes, alongside key trial design and implementation questions across congestive, kidney, and post-discharge endpoints.","cbCainhBjqi3Zplk","https://ap.wps.com/l/cbCainhBjqi3Zplk","pdf",2297633,1,17,"English","en","# Introduction\n## End points in ADHF trials\n## Optimization of existing medical therapy\n## Decongestion therapy monitoring strategies\n## Decongestion device therapies\n## Conclusions","[{\"question\":\"Why is congestion the main cause of symptoms and hospitalization in heart failure?\",\"answer\":\"Congestion results from excessive salt and water retention by the kidney, leading to fluid accumulation in the intravascular and interstitial space. These congestion-related signs and symptoms are the predominant reason for acute decompensated heart failure (ADHF) hospitalizations.\"},{\"question\":\"What problem remains despite loop diuretic therapy?\",\"answer\":\"About 25–30% of patients discharged after ADHF have residual signs of congestion, and inadequate decongestion is linked to a worse prognosis. Some congestion may also be unrecognized at discharge.\"},{\"question\":\"What barriers limit effective decongestion and how do devices aim to address them?\",\"answer\":\"Key barriers include lack of a clinically actionable decongestion endpoint, variation in clinical assessment, inaccurate diuretic response measures, diuretic resistance, limited continuous monitoring and titration, and worsening renal function leading to premature discontinuation of therapies. Devices generally target a hypothesized hemodynamic mechanism to improve diuretic response indirectly, though mechanistic evidence and clinical outcomes remain uncertain.\"}]",1781129923,43,{"code":4,"msg":28,"data":29},"ok",{"site_id":30,"language":22,"slug":31,"title":13,"keywords":32,"description":14,"schema_data":33,"social_meta":84,"head_meta":86,"extra_data":88,"updated_unix":25},105,"decongestion-in-heart-failure-medical-and-device-therapies","",{"@graph":34,"@context":83},[35,52,66],{"@type":36,"itemListElement":37},"BreadcrumbList",[38,42,46,49],{"item":39,"name":40,"@type":41,"position":19},"https://docshare.wps.com","Home","ListItem",{"item":43,"name":44,"@type":41,"position":45},"https://docshare.wps.com/document/","Document",2,{"item":47,"name":12,"@type":41,"position":48},"https://docshare.wps.com/document/healthcare/",3,{"item":50,"name":13,"@type":41,"position":51},"https://docshare.wps.com/document/decongestion-in-heart-failure-medical-and-device-therapies/32364/",4,{"url":50,"name":13,"@type":53,"author":54,"headline":13,"publisher":56,"fileFormat":59,"description":14,"dateModified":60,"datePublished":60,"encodingFormat":59,"isAccessibleForFree":61,"interactionStatistic":62},"DigitalDocument",{"name":9,"@type":55},"Person",{"url":39,"name":57,"@type":58},"DocShare","Organization","application/pdf","2026-06-10",true,{"@type":63,"interactionType":64,"userInteractionCount":4},"InteractionCounter",{"@type":65},"ViewAction",{"@type":67,"mainEntity":68},"FAQPage",[69,75,79],{"name":70,"@type":71,"acceptedAnswer":72},"Why is congestion the main cause of symptoms and hospitalization in heart failure?","Question",{"text":73,"@type":74},"Congestion results from excessive salt and water retention by the kidney, leading to fluid accumulation in the intravascular and interstitial space. These congestion-related signs and symptoms are the predominant reason for acute decompensated heart failure (ADHF) hospitalizations.","Answer",{"name":76,"@type":71,"acceptedAnswer":77},"What problem remains despite loop diuretic therapy?",{"text":78,"@type":74},"About 25–30% of patients discharged after ADHF have residual signs of congestion, and inadequate decongestion is linked to a worse prognosis. Some congestion may also be unrecognized at discharge.",{"name":80,"@type":71,"acceptedAnswer":81},"What barriers limit effective decongestion and how do devices aim to address them?",{"text":82,"@type":74},"Key barriers include lack of a clinically actionable decongestion endpoint, variation in clinical assessment, inaccurate diuretic response measures, diuretic resistance, limited continuous monitoring and titration, and worsening renal function leading to premature discontinuation of therapies. Devices generally target a hypothesized hemodynamic mechanism to improve diuretic response indirectly, though mechanistic evidence and clinical outcomes remain uncertain.","https://schema.org",{"og:url":50,"og:type":85,"og:title":13,"og:site_name":57,"og:description":14},"article",{"robots":87,"canonical":50},"index,follow",{"doc_id":7,"site_id":30}]